Burcon Nutrascience Corporation has reached a critical milestone by scaling up commercial production of its pea protein isolate at its Galesburg facility, enhancing its market strategy. This development, achieved in under 90 days, allows Burcon to address increasing customer demand and explore revenue opportunities in a market with a significant total addressable market.
The company has also initiated a share consolidation program at a 20:1 ratio, starting June 11, 2025, to optimize its capital structure. This move reflects Burcon's dedication to solidifying its financial standing. A partnership with ProMan, involving the lease of a protein production facility, supports Burcon's capital-light strategy while ensuring control over its plant-based protein production. Production is expected to begin within 90 days, with Burcon setting ambitious revenue targets.
Burcon's commercialization efforts include collaborations to explore new applications for its proteins and the introduction of innovative products like Solatein™ sunflower protein isolate. Despite a net loss in 3Q25, the company has shown financial improvement and, with a pro-forma cash balance of about $10.0M, is poised for continued growth in the plant-based protein sector.
